Open AccessTreatment of Endometrial Hyperplasia with Cyproterone Acetate Histological and Hormonal Aspects
Author(s) -
Jasonni Valerio M.,
Franceschetti Francá,
Ciotti Patrizia,
Bulletti Carlo,
Vignudelli Adele,
Marabini Alberto,
Naldi Silvia,
Flamigni Carlo
Publication year - 1986
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016348609161484
Subject(s) - cyproterone acetate , medicine , estrone , progestin , androstenedione , estrogen , endocrinology , endometrial hyperplasia , testosterone (patch) , hyperplasia , menopause , medroxyprogesterone acetate , hormone , androgen
A regime of cyproterone acetate (CPA) (300 mg/‐day by the oral route for 30 days) has been used in 10 postmenopausal women with endometrial hyperplasia (8 atypical and 2 adenomatous). Androstenedione (A), estrone (E 1 ), testosterone (T) and estradiol (E 2 ) plasma levels were determined before and at the end of treatment. The regression of endometrial hyperplasia was ascertained histologically in all patients after 30 days of therapy. All steroids showed a significant decrease (p<0.05) as compared with their corresponding basal values. Moreover, the E 1 A ratio was significantly lowered (p<0.01) following CPA administration (5.9+2.9% to 2.5+0.6%). From these data it is evident that CPA can not only act as a progestin, but may also reduce the endogenous estrogen production, lowering either the adrenal production of A (the most important estrogen precursor in the post‐menopause) or the A to E 1 peripheral conversion.